NASDAQ: MRNA
Moderna is a biotechnology company that develops and sells mRNA-based medicines. It has vaccines and therapeutics across infectious diseases, oncology and rare diseases.
Its commercial portfolio consists of respiratory vaccines:
- Spikevax, its COVID-19 vaccine.
- mNEXSPIKE, a next-generation COVID vaccine.
- mRESVIA, for RSV.
- mFLUSIVA, a seasonal influenza vaccine approved by the U.S. FDA in 2026 and also approved in Canada.
- A flu/COVID combination vaccine, approved as mCOMBRIAX in the EU and mCOFLU in Canada.
Revenue comes from product sales to governments and healthcare markets in the U.S. and internationally. This includes long-term strategic government partnerships with the United Kingdom, Canada and Australia, plus a five-year COVID vaccine manufacturing agreement in Mexico. Smaller amounts come from grants, collaborations, licensing, royalties and stand-ready manufacturing.
The late-stage pipeline includes:
- Intismeran autogene, an individualized neoantigen therapy developed with Merck, with positive Phase 3 data in resected high-risk melanoma.
- mRNA-4359, a cancer antigen therapy.
- mRNA-3927 for propionic acidemia.
- mRNA-3705 for methylmalonic acidemia. Updated
First profitable quarter in years, with net income of $162 million against a year-ago loss, and management lifted full-year revenue growth guidance. International COVID deliveries under the UK, Canada and Australia partnerships did the heavy lifting, while the melanoma vaccine with Merck cut recurrence or death risk.
Moderna cleared $258.38, a fresh 52-week high and 5.11% above the peak it set on October 21. The $103.2 billion vaccine maker keeps resetting its own ceiling faster than two weeks at a time.
Duolingo closed up 26.8% at $162.31, the biggest move in a 383-stock priority universe that saw double-digit swings on both ends. Datadog, Vertiv, CVS and Quanta all gave up more than 12% in the same session.
Royal Caribbean is the standout at the open, up 7.56% to $301.81 and leading a 381-stock priority list. HSBC anchors the other end at -6.47%, a 14-point spread between the day's best and worst names.
The call that matters for holders here is supply: Cramer argues the equity and debt markets are nearly tapped out after Meta, Alphabet and SpaceX raisings, with Anthropic's S1 now in line. He stops short of calling a top while pushing for buybacks and takeovers over further deals, favoring staged buying in Applied Materials and patience on Moderna.
American Tower opened up 8.07%, the only move above 4% on the upside across a 385-name board. Bloom Energy is off 11.67%, with Moderna, Infosys, GE Aerospace and AT&T sliding too.
Moderna's 17.8% drop was the single biggest move at Tuesday's close, and four of the five worst performers were chip and photonics names. Spotify topped the winners.
A 14.31% slide to $205.67 takes roughly $12 billion off an $84.9 billion biotech in a single session, one of the sharpest single-day drops this name has seen. Keep an eye on whether the $240 open gets reclaimed.
Moderna just set a fresh 52-week high at $242.08, 2.36% above the peak it reached on October 15. A year ago the stock traded near $27.
General Motors shed 7.5% into the close, the worst showing across 387 priority names and nearly double the next-biggest decline. GoPro and Clover Health anchored the other end, each up more than 7.5%.
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.…
One stock has soared more than sevenfold this year, another just lost a quarter of its value on leaked data, and a third carries the fate of millions of retirees. Friday's earnings…
Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.52, up 5% in afternoon trading, as the…
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has…
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands…
Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast. Three pharma giants report Thursday, and…
Pre-Market Stock Futures: Futures are trading higher after a Monday bounce that saw all major indices finish higher; stocks closed well below their intraday highs, but it was a positive start after…
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial. Moderna (NASDAQ:MRNA | MRNA…
Merck (NYSE:MRK | MRK Price Prediction) reports third-quarter results on Thursday, Oct. 29. KEYTRUDA still anchors the business, but I’ll be watching whether newer launches are growing fast enough to cushion the…
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn’t stopped. Those numbers landed short of the…
A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked favorable on…
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.89 during the trading…
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide…
Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10%…
Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA…
Moderna is a biotechnology company that develops and sells mRNA-based medicines. It has vaccines and therapeutics across infectious diseases, oncology and rare diseases.
